ArticleJournal of the National Comprehensive Cancer Network : JNCCN2020
Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation.
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Associations between inflammatory biomarkers, symptoms, treatment toxicities and quality of life in people with advanced cancer receiving systemic anti-cancer treatments: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Global research and emerging trends in depression in lung cancer: a bibliometric and visualized study from 2014 to 2024.Frontiers in oncology · 2025Pooled it
- Prognostic Value of Pretreated Blood Inflammatory Markers in Patients with Bone Sarcoma: A Meta-Analysis.Disease markers · 2021Pooled it
- Brain Metabolic Activity Measured by [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Novel prognostic signature unveils PSEN1 contributes to depression-induced lung adenocarcinoma progression.Frontiers in immunology · 2026Article
- Development and validation of machine learning models based on blood routine tests and tumor markers in early screening of primary bronchogenic lung cancer.Translational lung cancer research · 2025Article
- Senkyunolide H reverses depression-induced breast cancer progression by regulating CXCR2.Natural products and bioprospecting · 2025Article
- Investigating the prevalence and correlates of anxiety and depression among COVID-19 patients with and without concomitant tumor conditions.Frontiers in psychology · 2025Article
- Chronic stress promotes non-small cell lung cancer (NSCLC) progression through circMBOAT2 upregulation mediated by CTCF.Cancer gene therapy · 2024Article
- The Impact of a Diet Rich in Omega-3 Fatty Acids on the Quality of Life of Patients with Squamous Cell Lung Cancer and Comorbid Depression: A Retrospective Study.Actas espanolas de psiquiatria · 2024Article
- Strength of selection in lung tumors correlates with clinical features better than tumor mutation burden.Scientific reports · 2024Article
- Smoking as a mediator in the association between major depressive disorder and schizophrenia on lung cancer risk: a bidirectional/multivariable and mediation Mendelian randomization study.Frontiers in psychiatry · 2024Article
- Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer.Clinics (Sao Paulo, Brazil) · 2024Article
- Efficacy comparison of five antidepressants in treating anxiety and depression in cancer and non-cancer patients.Frontiers in neuroscience · 2024Article
- Derived Neutrophil-Lymphocyte Ratio and C-Reactive Protein as Prognostic Factors for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.Diagnostics (Basel, Switzerland) · 2023Article
- Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review.Cancers · 2022Article
- Managing Cancer Drug Resistance from the Perspective of Inflammation.Journal of oncology · 2022Review
- Application of Narrative Nursing Combined With Focused Solution Model to Anxiety and Depression in Patients With Lung Tumor During Perioperative Period.Frontiers in surgery · 2022Article
- Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.Scientific reports · 2021Article
- Neutrophil to Lymphocyte Ratio in Lung Cancer: Implications for Depressive Symptoms and Survival.Clinical oncology and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPatients with lung cancer with greater systemic inflammation have higher rates of depression. Tumor mutation burden (TMB) predicts immunotherapy response in patients with lung cancer and is associated with intratumoral inflammation, which may contribute to systemic inflammation and depression. This study evaluated whether higher TMB was associated with increased depression and systemic inflammation in patients with lung cancer. PATIENTS AND
methodsPatients with metastatic lung cancers were evaluated for depression severity using the Hospital Anxiety and Depression Scale. TMB was measured using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. Inflammation was evaluated using C-reactive protein (CRP) level and neutrophil-to-lymphocyte ratio (NLR).
resultsA total of 96 patients with adequate TMB testing were evaluated. The average number of mutations (TMB) was 10.8 (SD, 10.9). A total of 19% of patients endorsed clinically significant depression symptoms. TMB was significantly correlated with depression severity (r = 0.34; P=.001) and NLR (r = 0.37; P=.002) but not CRP level (r = 0.19; P=.07). TMB was also higher in patients receiving chemotherapy (mean, 12.0) and immunotherapy (mean, 14.4) versus targeted therapy (mean, 4.8). A multivariate model found that TMB (β = 0.30; P=.01) and CRP level (β = 0.31; P=.01) were independently associated with depression; there was no significant interaction effect of TMB × CRP and depression. A similar multivariate model showed no independent effect for NLR and depression (β = 0.16; P=.17) after accounting for TMB.
conclusionsThese data provide evidence for biologic depression risk in patients with lung cancer who have high levels of TMB. The underlying mechanism of the association is not clearly related to inflammation but warrants further analysis to broadly elucidate the mechanism of biologically derived depression in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.